[Review] CSF and blood biomarkers for Parkinson’s disease
In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease—the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain.
Ander nieuws
[Comment] A new step towards targeting tau
Progressive supranuclear palsy is a rare neurodegenerative disease characterised by an axial parkins...
Parkinson’s disease patient: ‘I can walk… it’s really helped me’
Parkinson's disease patient Gail Jardine can walk more freely after having a spinal implant fit...
Housebound Parkinson’s patients have movement restored
An electrical stimulus can help revive mobility for people with the disease, scientists have discove...